Core Viewpoint - iSpecimen Inc. has announced a public offering of 5,714,283 shares at a price of $0.70 per share, aiming to raise approximately $4 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering is priced at $0.70 per share, with expected gross proceeds of around $4 million [1]. - The offering is set to close on July 25, 2025, pending customary closing conditions [1]. - WestPark Capital, Inc. is acting as the Sole Book-Runner for the offering [2]. Group 2: Use of Proceeds - The company plans to allocate $1,500,000 for marketing and advertising services from IR Agency LLC [2]. - An initial milestone payment of $1,000,000 will be made to Sales Stack Solutions Corp. [2]. - Remaining funds will be used for working capital and general corporate purposes [2]. Group 3: Company Overview - iSpecimen operates an online marketplace connecting scientists with healthcare specimen providers for medical research [5]. - The company utilizes proprietary cloud-based technology to facilitate searches for biospecimens across a network of healthcare organizations [5].

Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [5] Offering Details - Trevi announced a public offering of 17,400,000 shares of common stock at a price of $5.75 per share, aiming for total proceeds of $100 million before deductions [1] - The offering includes a 30-day option for underwriters to purchase up to 2,610,000 additional shares at the public offering price [1] - The offering is expected to close on or about June 5, 2025, subject to customary closing conditions [1] Underwriters - Morgan Stanley, Leerink Partners, Stifel, and Cantor are acting as joint book-running managers for the offering [2] Regulatory Information - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on August 15, 2023 [3]

Core Viewpoint - Cemtrex, Inc. has announced a public offering of common stock expected to raise approximately $1.25 million before expenses [1][3]. Group 1: Offering Details - The offering consists of 1,250,000 shares of common stock priced at $1.00 per share [2]. - Aegis Capital Corp. has been granted a 45-day option to purchase up to 15% additional shares to cover over-allotments [2]. - The transaction is expected to close on or about May 29, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, paying down indebtedness, and working capital [3]. Group 3: Company Overview - Cemtrex, Inc. operates in the Security and Industrial sectors, providing advanced security technology and industrial services [7]. - The Security segment, led by Vicon Industries, offers video management software and integrated surveillance solutions [7]. - The Industrial segment provides expert rigging, millwrighting, and equipment installation services to manufacturers [7].

Core Viewpoint - Gyre Therapeutics has initiated an underwritten public offering of its common stock to fund its clinical trials and operational needs [1][2]. Group 1: Offering Details - Gyre is granting underwriters a 30-day option to purchase additional shares at the public offering price, subject to market conditions [1]. - The offering is made under a shelf registration statement effective since November 22, 2024, and will be conducted via a prospectus [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance Gyre's Phase 2 clinical trial of F351 for MASH-associated liver fibrosis, along with funding for research, development, manufacturing, and general corporate purposes [2]. Group 3: Management of the Offering - Jefferies is the lead book-running manager for the offering, with H.C. Wainwright & Co. serving as co-manager [3]. Group 4: Company Overview - Gyre Therapeutics is focused on developing and commercializing treatments for liver fibrosis, including MASH, and has a pipeline that includes various therapeutic programs in the U.S. and China [6].